N.N'-Dimethyl-cyclohexan-cis-trans-1.4-bis-methylamin | 17096-34-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N.N'-Dimethyl-cyclohexan-cis-trans-1.4-bis-methylamin
• 英文别名: N-methyl-1-[4-(methylaminomethyl)cyclohexyl]methanamine
• CAS: 17096-34-3
• 化学式: C₁₀H₂₂N₂
• 分子量: 170.298
• InChiKey: RYEPWYWCNMDXLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS
  申请人：Kim Beon-Kyu

  公开号：US20090072206A1

  公开（公告）日：2009-03-19

  Various non-limiting embodiments disclosed herein relate to ophthalmic devices comprising photochromic materials having extended pi-conjugated systems. For example, various non-limiting embodiments disclosed herein provide a photochromic material, such as an indeno-fused naphthopyran, which comprises a group that extends the pi-conjugated system of the indeno-fused naphthopyran bonded at the 11-position of thereof. Further, the photochromic materials according to certain non-limiting embodiments disclosed herein may display hyperchromic absorption of electromagnetic radiation as compared to conventional photochromic materials and/or may have a closed-form absorption spectrum that is bathochromically shifted as compared to conventional photochromic materials. Other non-limiting embodiments relate to methods of making the ophthalmic devices comprising photochromic materials.

  本文披露了各种非限制性实施例，涉及具有扩展π-共轭系统的光致变色材料的眼科设备。例如，本文披露的各种非限制性实施例提供了一种光致变色材料，例如一种吲哚并螺[2,1,3]环庚烷，其在其11位处连接了一个扩展吲哚并螺[2,1,3]环庚烷的π-共轭系统的基团。此外，根据本文披露的某些非限制性实施例，光致变色材料可能与传统光致变色材料相比，显示出电磁辐射的高色素吸收，并且/或者具有与传统光致变色材料相比向低波长移动的闭合吸收光谱。其他非限制性实施例涉及制造包含光致变色材料的眼科设备的方法。
• Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use
  申请人：Moinet Christophe

  公开号：US20070043095A1

  公开（公告）日：2007-02-22

  The present invention is drawn to compounds of the formula in racemic and enantiomeric form or all combinations of these forms wherein the various substituents are as defined in the application which compounds have a good affinity for certain subtypes of somatostatin receptors and have useful pharmacological properties.

  本发明涉及公式中的化合物，包括外消旋和对映体形式或这些形式的所有组合，其中各种取代基的定义如申请书所述。这些化合物对某些生长抑素受体亚型具有良好的亲和力，并具有有用的药理学性质。
• Organic Compounds
  申请人：Collingwood Stephen Paul

  公开号：US20080312217A1

  公开（公告）日：2008-12-18

  A Compound of formula (I) or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M 1 , M 1 , L 1 , L 2 , W 1 , W 2 , X 1 , X 2 , Y 1 , Y 2 , A, R 5 , and R 5a are as defined herein for the treatment of conditions mediated by the blockade of an epithelial sodium channel, particularly an inflammatory or allergic condition.

  化合物式（I）或其互变异构体、立体异构体、溶剂化物或药学上可接受的盐，其中M1、M1、L1、L2、W1、W2、X1、X2、Y1、Y2、A、R5和R5a的定义如本文所述，用于治疗由于阻断上皮钠通道介导的情况，特别是炎症或过敏症。
• [EN] SENOTHERAPEUTIC COMPOUND<br/>[FR] COMPOSÉ SÉNOTHÉRAPEUTIQUE
  申请人：BIONEXA S R L

  公开号：WO2022118186A1

  公开（公告）日：2022-06-09

  It is provided a senotherapeutic compound comprising a synthetic derivative of flavones, according to the formula (I), in which at least two of R2-R6 are H, and the remainder are individually selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I, where R1 is a radical.

  提供一种含有黄酮类合成衍生物的治疗化合物，其化学式为(I)，其中R2-R6中至少有两个为H，其余的分别从以下中选择：H，OH，R1，OR1，NO2，NH2，NHR1，F，Cl，Br，I，其中R1是一个基团。
• PRODUCTION METHOD FOR 2-ALKENYLAMINE COMPOUND
  申请人：Showa Denko K.K.

  公开号：EP2752402B1

  公开（公告）日：2018-06-27